Krishna Institute of Medical Sciences Ltd.

“KIMS operates a disciplined, high-ROIC brownfield hospital model in structurally underpenetrated South Indian Tier 2/3 markets, led by a founder-promoter with aligned incentives and a clean balance sheet. The business earns above-average returns with below-average risk of permanent impairment. The fatal flaw today is price: at 90x trailing and 53x forward P/E, the market has already capitalised a decade of optimistic execution, leaving a 5-year expected return of roughly 1.7% annualised and a 10-year base case of ~7% CAGR — insufficient compensation for geographic concentration risk and government reimbursement exposure. Re-entry below INR 450–475 would shift the risk-reward decisively in the investor's favour.”